Tobacco Addiction and Pharmacogenetics of Nicotine Metabolism

References

• Amos C. I., Wu X., Broderick P., Gorlov I. P., Gu J., Eisen T., et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Gen 2008; 40: 616–622
   PubMed Web of Science ®Google Scholar
• Aubin H. J., Bobak A., Britton J. R., Oncken C., Billing C. B., Jr., Gong J., et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63: 717–724
   PubMed Web of Science ®Google Scholar
• Benowitz N. L., Jacob P., III. Individual differences in nicotine kinetics and metabolism in man. Pharmacokinetics, Metabolism, and Pharmaceutics of Drugs of Abuse, R. S. Rapaka, N. Chiang, B. R. Martin. United States Department of Health and Human Services: National Institute on Drug Abuse, Bethesda, MDUSA 1997; 48–64
   Google Scholar
• Benowitz N. L., Lessov C. N., Swan G. E., Jacob P., III. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 2006a; 79: 480–488
   PubMed Web of Science ®Google Scholar
• Benowitz N. L., Swan G. E., Jacob P., III, Lessov-Schlaggar C. N., Tyndale R. F. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 2006b; 80: 457–467
   PubMed Web of Science ®Google Scholar
• Benowitz N. L., Lessov-Schlaggar C. N., Swan G. E. Genetic influences in the variation in renal clearance of nicotine and cotinine. Clin Pharmacol Ther 2008; 84: 243–247
   PubMed Web of Science ®Google Scholar
• Berrettini W., Yuan X., Tozzi F., Song K., Francks C., Chilcoat H., et al. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol Psychiatry 2008; 13: 368–373
   PubMed Web of Science ®Google Scholar
• Bierut L. J., Madden P. A. F., Breslau N., Johnson E. O., Hatsukami D., Pomerleau O. F., et al. Novel genes identified in a high density genome-wide association study for nicotine dependence. Hum Mol Genet 2007; 16: 24–35
   PubMed Web of Science ®Google Scholar
• Bierut, L. J., Stitzel, J. A., Wang, J. C., Hinrichs, A. L., Bertelsen, S., Fox, L., , et al.in press. An amino acid change in the alpha 5 nicotinic receptor increases risk for nicotine dependence. Am J Psychiatry.
   Google Scholar
• Cascorbi H. F., Vesell E. S., Blake D. A., Helrich M. Genetic and environmental influence on halothane in twins. Clin Pharmacol Ther 1971; 12: 50–55
   PubMed Web of Science ®Google Scholar
• Chanock S. J., Hunter D. J. Genomics: when the smoke clears. Nature 2008; 452: 537–538
   PubMed Web of Science ®Google Scholar
• David S. P., Brown R. A., Papandonatos G. D., Kahler C. W., Lloyd-Richardson E. E., Munafò M. R., et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tobacco Res 2007; 9: 821–833
   PubMed Web of Science ®Google Scholar
• Dorus E., Pandey G. N., Davis J. M. Genetic determinants of lithium ion distribution. Arch Gen Psychiatry 1975; 32: 1097–1102
   PubMed Web of Science ®Google Scholar
• Evans W. E., Johnson J. A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9–39
   PubMed Web of Science ®Google Scholar
• Evans W. E., Relling M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–491
   PubMed Web of Science ®Google Scholar
• Frueh, F. W. 2006. Pharmacogenomics: patient selection for clinical trial participation and enrichment strategies. Available at: http://www.fda.gov/cder/genomics/presentations.htm. Accessed on August 12, 2008.
   Google Scholar
• Grassi G., Seravalle G., Calhoun D. A., Bolla G. B., Giannattasio C., Marabini M., et al. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation 1994; 90: 248–253
   PubMed Web of Science ®Google Scholar
• Hart M. N., Wang S., Nakamoto K., Wesselman C., Li Y., Zhong X. Genetic polymorphisms in cytochrome P450 oxidoreductase infleunce microsomal P450-catalyzed drug metabolism. Pharmacogenet Genomics 2008; 18: 11–24
   PubMed Web of Science ®Google Scholar
• Heatherton T. F., Kozlowski L. T., Frecker R. C., Fagerström K. O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction 1991; 86: 1119–1127
   PubMedGoogle Scholar
• Howard L. A., Ahluwalia J. S., Lin S. K., Sellers E. M., Tyndale R. F. CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics 2003; 13: 321–328
   PubMedGoogle Scholar
• Huang S.-M., Goodsaid F., Rahman A., Frueh F., Lesko L. J. Application of pharmacogenomics in clinical pharmacology. Toxicol Mech Meth 2006; 16: 89–99
   PubMed Web of Science ®Google Scholar
• Hughes, J. R., Stead, L. F., Lancaster, T. 2007. Antidepressants for smoking cessation. Cochrane Database Syst Rev, CD000031.
   Google Scholar
• Hung R. J., McKay J. D., Gaborieau V., Boffetta P., Hashibe M., Zaridze D., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452: 633–637
   PubMed Web of Science ®Google Scholar
• Hukkanen J., Jacob P., III, Benowitz N. L. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57: 79–115
   PubMed Web of Science ®Google Scholar
• Itoh M., Nakajima M., Higashi E., Yoshida R., Nagata K., Yamazoe Y., et al. Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. J Pharmacol Exp Ther 2006; 319: 693–702
   PubMed Web of Science ®Google Scholar
• Javitz H. S., Swan G. E., Zbikowski S. M., et al. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. Am J Manag Care 2004a; 10: 217–226
   PubMed Web of Science ®Google Scholar
• Javitz H. S., Swan G. E., Zbikowski S. M., et al. Return on investment of different combinations of bupropion SR dose and behavioral treatment for smoking cessation in a health care setting: an employer's perspective. Value Health 2004b; 7: 535–543
   PubMed Web of Science ®Google Scholar
• Lerman C., Shields P. G., Wileyto E. P., Audrain J., Hawk L. H., Jr, Pinto A., et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol 2003; 22: 541–548
   PubMed Web of Science ®Google Scholar
• Lerman C., Tyndale R., Patterson F., Wileyto E. P., Shields P. G., Pinto A., et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 2006; 79: 600–608
   PubMed Web of Science ®Google Scholar
• Lessov-Schlaggar C. N., Pergadia M. L., Khroyan T. V., Swan G. E. Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol 2008; 75: 178–195
   PubMed Web of Science ®Google Scholar
• Li G. H., Faulhaber H. D., Rosenthal M., Schuster H., Jordan J., Timmermann B., et al. Beta-2 adrenergic receptor gene variations and blood pressure under stress in normal twins. Psychophysiology 2001; 38: 485–489
   Google Scholar
• Malaiyandi V., Goodz S. D., Sellers E. M., Tyndale R. F. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol Biomarkers Prev 2006; 15: 1812–1819
   Google Scholar
• Mathers C. D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: 2011–2030
   Web of Science ®Google Scholar
• McCaffery J. M., Pogue-Geile M. F., Ferrell R. E., Petro N., Manuck S. B. Variability within alpha- and beta-adrenoreceptor genes as a predictor of cardiovascular function at rest and in response to mental challenge. J Hypertens 2002; 20: 1105–1114
   Google Scholar
• McCaffery J. M., Bleil M., Pogue-Geile M. F., Ferrell R. E., Manuck S. B. Allelic variation in the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cardiovascular reactivity in young adult male and female twins of European-American descent. Psychosom Med 2003; 65: 721–728
   Google Scholar
• McClure J., Swan G. E. Tailoring nicotine replacement therapy: rationale and potential approaches. CNS Drugs 2006; 20: 281–291
   PubMed Web of Science ®Google Scholar
• Meyer U. A. Pharmacogenetics—five decades of therapeutic lessons from genetic diversity. Nat Rev Genet 2004; 5: 669–676
   PubMed Web of Science ®Google Scholar
• Moolchan E. T., Hudson D. L., Schroeder J. R., Sehnert S. S. Heart rate and blood pressure responses to tobacco smoking among African-American adolescents. J Natl Med Assoc 2004; 96: 767–771
   Google Scholar
• Mwenifumbo J. C., Lessov-Schlaggar C. N., Zhou Q., Krassnow R. E., Swan G. E., Benowitz N. L., et al. Identification of novel CYP2A6*1B variants; the CYP2A6*1B allele is associated with faster in, vivo nicotine metabolism. Clin Pharmacol Ther 2008; 83: 115–121
   PubMed Web of Science ®Google Scholar
• Nakajima M., Tanaka E., Kwon J. T., Yokoi T. Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. Drug Metab Dispos 2002; 30: 1484–1490
   PubMed Web of Science ®Google Scholar
• Neale M. C., Cardon L. Methodology for Genetic Studies of Twins and Families. Kluwer Academic Publishers, Dordect/Boston/London 1992
   Google Scholar
• Neale M. C., Boker S. M., Xie G., Maes H. H. Mx: Statistical Modeling6th ed. Department of Psychiatry, Virginia Commonwealth University, Richmond, VirginiaUSA 2002
   Google Scholar
• Niaura R., Shadel W. G., Goldstein M. G., Hutchinson K. E., Abrams D. B. Individual differences in responses to the first cigarette following overnight abstinence in regular smokers. Nicotine Tobacco Res 2001; 3: 37–44
   Google Scholar
• O'Loughlin J., Paradis G., Kim W., DiFranza J., Meshefedjian G., McMillan-Davey E., et al. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tobacco Contr 2004; 13: 422–428
   PubMed Web of Science ®Google Scholar
• Pomerleau O. F., Collins A. C., Shiffman S., Pomerleau C. S. Why some people smoke and others do not: new perspectives. J Consult Clin Psychol 1993; 61: 723–731
   PubMed Web of Science ®Google Scholar
• Rieder M. J., Reiner A. P., Gage B. F., Nickerson D. A., Eby C. S., McLeod H. L., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285–2293
   PubMed Web of Science ®Google Scholar
• Rubin, D. 2002. PharmGKB: The Pharmacogenetics Knowledge Base. Available at: http://infolab.stanford.edu/infoseminar/Archive/WinterY2002/rubin.pdf. Accessed on August 12, 2008.
   Google Scholar
• Saccone S. F., Hinrichs A. L., Saccone N. L., Chase G. A., Konvicka K., Madden P. A. F., et al. Cholinergic nicotinic receptor genes implicated in a nicotine-dependence association study targeting 348 candidate genes with 3,713 SNPs. Hum Mol Genet 2007; 16: 36–49
   PubMed Web of Science ®Google Scholar
• SAS Institute, SAS for Windows, version 9.1. Cary, North CarolinaUSA: SAS Institute, Inc., copyright 2002–2003.
   Google Scholar
• Silagy, C., Lancaster, T., Stead, L., Mant, D., Fowler, G. 2004. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, CD000146.
   PubMedGoogle Scholar
• Snieder H., Harshfield G. A., Barbeau P., Pollock D. M., Pollock J. S., Treiber F. A. Dissecting the genetic architecture of the cardiovascular and renal stress response. Biolog Psychol 2002; 61: 73–95
   Google Scholar
• Stolerman I. P., Jarvis M. J. The scientific case that nicotine is addictive. Psychopharmacology 1995; 117: 2–10
   PubMed Web of Science ®Google Scholar
• Swan G. E., Jack L. M., Ward M. M. Subgroups of smokers with different success rates after use of transdermal nicotine. Addiction 1997; 92: 207–218
   PubMed Web of Science ®Google Scholar
• Swan G. E., Benowitz N. L., Jacob P., III, Lessov C. N., Tyndale R. F., Wilhelmsen K., et al. Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Res 2004; 7: 435–448
   Google Scholar
• Swan G. E., Benowitz N. L., Lessov C. N., Jacob P., III, Tyndale R. F., Wilhelmsen K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 2005a; 15: 115–125
   Google Scholar
• Swan G. E., Valdes A. M., Ring H. Z., Khroyan T. V., Jack L. M., Ton C. C., et al. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 2005b; 5: 21–29
   PubMed Web of Science ®Google Scholar
• Swan G. E., Hops H., Wilhelmsen K. C., Lessov C. N., Cheng L.S-C., Hudmon K. S., et al. A genome-wide screen for nicotine dependence susceptibility loci. Am J Med Genet B Neuropsychiatric Genet 2006; 141: 354–360
   Google Scholar
• Swan G. E., Jack L. M., Valdes A. M., Ring H. Z., Ton C. C., Curry S. J., et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol 2007a; 26: 361–368
   PubMed Web of Science ®Google Scholar
• Swan G. E., Lessov-Schlaggar C. N., Krasnow R. E., Wilhelmsen K. C., Jacob P., III, Benowitz N. L. Genetic and environmental sources of variation in heart rate response to infused nicotine in twins. Cancer Epidemiol Biomarkers Prev 2007b; 16: 1057–1064
   Google Scholar
• Swan G. E., Jack L. M., Javitz H., McAfee T., McClure J. M. Predictors of 12-month outcome in smokers who received bupropion SR for smoking cessation. CNS Drugs 2008; 22: 239–256
   PubMedGoogle Scholar
• Swan, G. E., Lessov-Schlaggar, C. N., Bergen, A. W., He, Y., Tyndale, R. F., Benowitz, N. L. in press. Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics.
   Google Scholar
• Thorgeirsson T. E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K. P., et al. Variant associated with nicotine dependence, lung cancer, and peripheral arterial disease. Nature 2008; 452: 638–642
   PubMed Web of Science ®Google Scholar
• Uhl G. R., Drgon T., Johnson C., Fatusin O. O., Liu Q. R., Contoreggi C., et al. “Higher order” addiction molecular genetics: convergent data from genomewide association in humans and mice. Biochem Pharmacol 2008a; 75: 98–111
   PubMed Web of Science ®Google Scholar
• Uhl G. R., Liu Q. R., Drgon T., Johnson C., Walther D., Rose J. E., et al. Molecular genetics of successful smoking cessation: convergent genomewide association study results. Arch Gen Psychiatry 2008b; 65: 683–693
   PubMedGoogle Scholar
• Vesell E. S., Page J. G., Passanti T. G. Genetic and environmental factors affecting ethanol metabolism in man. Clin Pharmacol Ther 1971; 12: 192–201
   PubMed Web of Science ®Google Scholar
• Vesell E. S. The influence of host factors on drug response. VII. Implications for interpretation of clinical trials and other published studies on drug response in man. Rational Drug Ther 1981; 15: 1–5
   Google Scholar
• Weber W. W. Pharmacogenetics. Oxford University Press, New York 1997
   Google Scholar
• Weinshilboum R. M., Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Human Genet 2006; 7: 223–245
   PubMed Web of Science ®Google Scholar
• Williams R. B., Marchuk D. A., Gadde K. M., Barefoot J. C., Grichnik K., Helms M. J., et al. Central nervous system serotonin function and cardiovascular responses to stress. Psychosom Med 2001; 63: 300–305
   PubMed Web of Science ®Google Scholar
• World Health Organization. The Tobacco Atlas . 2002. Available at: http://www.who.int/tobacco/statistics/tobacco_atlas. Accessed on December 17, 2008.
   Google Scholar
• Yamanaka H., Nakajima M., Fukami T., Sakai H., Nakamura A., Katoh M., et al. CYP2A6 and CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos 2005; 33: 1811–1818
   PubMed Web of Science ®Google Scholar
• Yin T., Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1—rationale and perspectives. Thromb Res 2007; 120: 1–10
   PubMed Web of Science ®Google Scholar
• Zevin S., Schaner M. E., Giacomini K. M. Nicotine transport in a human choriocarcinoma cell line (JAR). J Pharmaceut Sci 1998; 87: 702–706
   Google Scholar
• Zhang L., Rao F., Wessel J., Kennedy B. P., Rana B. K., Taupenot L., et al. Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiolog Genomics 2004; 19: 277–291
   PubMed Web of Science ®Google Scholar